BVF PARTNERS L P/IL

October 16, 2026

Raymond James initiates coverage on Kymera with Outperform rating. Raymond James has started covering Kymera Therapeutics, assigning an Outperform rating and a price target of $140. This new analyst note adds to the current consensus, which has an average target of $139.35 from 23 analysts. Recent discussions also question whether the company's pipeline is over-hyped or developing into a major therapeutic success.

September 25, 2026

MLTX noted in psoriatic arthritis market landscape report. A recent DelveInsight analysis outlined six late‑stage drugs expected to drive growth in the psoriatic arthritis market. The report highlights the expanding opportunity for immunotherapy developers, which includes companies such as MoonLake Immunotherapeutics. This broader market view may influence how investors view MLTX's pipeline prospects.

October 16, 2026

CBIO Announces New Clinical Trial Milestones for CR-001. Crescent Biopharma said it is enrolling patients in the standard‑of‑care chemotherapy arms of its global Phase 1/2 ASCEND trial for CR‑001, a PD‑1 × VEGF bispecific antibody. The company also began additional antibody‑drug‑conjugate combination studies with CR‑001. These steps indicate progress in the drug’s development and broaden its potential clinical applications.

October 15, 2026

OLMA Joins 12 Healthcare Stocks Moving in Pre-Market. OLMA was among 12 healthcare stocks that moved in Wednesday's pre‑market session, signaling early interest from traders. The move comes while the stock sits near its 52‑week low and a low RSI of 19.1, suggesting it may be oversold. This early activity could reflect new market sentiment or a reaction to broader healthcare sector dynamics.

October 13, 2026

Palvella Therapeutics Shares New Data at Dermatology Conference. Palvella Therapeutics presented three posters at the Fall Clinical Dermatology 2026 conference, sharing new data on microcystic lymphatic malformations and DSAP. This update highlights ongoing research in the company's key therapeutic areas. Meanwhile, HC Wainwright lowered its price target to $246 while maintaining its stance on the stock.

September 25, 2026

FDMT listed in Benzinga pre-market movers. 4D Molecular Therapeutics was mentioned in a Benzinga report on stocks moving lower in Friday’s pre-market session. The article grouped FDMT with other companies like Scholastic and Zscaler, noting a generally downbeat tone among legacy education and other large-cap names. This indicates the stock was part of a broader market movement rather than reacting to a company-specific announcement.

September 27, 2026

ELDN Presents Phase 2 Data, Gets FDA Fast Track for Tegoprubart. Eledon presented updated long‑term results from its Phase 2 BESTOW extension study at the International Congress of The Transplantation Society. The data support the continued development of tegoprubart for kidney transplant patients. The FDA also granted Fast Track designation for tegoprubart, and the company plans to start a Phase 3 LEGACY study in the fourth quarter of 2026. These milestones highlight progress in the company’s clinical program.

October 11, 2026

LLY Stock Dip News Unrelated to GPCR. Recent headlines focus on Eli Lilly (LLY) stock performance, which does not provide specific news about Structure Therapeutics (GPCR). While GPCR technical indicators show extreme oversold conditions, the provided news articles do not contain company-specific updates or developments for this symbol.

September 25, 2026

Cullinan delays arthritis data update to December. Cullinan Therapeutics announced it will delay its arthritis data update for zipalertinib to December due to ongoing safety concerns. This decision follows the release of strong Phase 3 lung cancer data, which initially saw the stock drop 18.2%. The company also confirmed plans for Q4 2026 updates across three T cell engager programs.

October 3, 2026

CAPS Reports 7.6% Organic Revenue Growth and Cuts Convertible Debt. Capstone Holding Corp. posted 7.6% organic revenue growth and 6.5% organic gross profit growth for July–August, showing continued expansion of its core business. The company also retired about 85% of its $6.82 million convertible note principal, leaving a $1 million balance and reducing leverage. These moves improve the company’s financial position and may support future earnings.